

Corrigendum for HIV-1 resistance and virological failure to treatment with the integrase inhibitors bicitegravir, cabotegravir, and dolutegravir: a systematic literature review

José L. Blanco-Arévalo¹, Miguel García-Deltoro², Miguel Torralba³, Manuel Vélez-Díaz-Pallarés⁴, Antonio Castro⁵, Darío Rubio-Rodríguez^{6*}, and Carlos Rubio-Terrés⁶

¹Infectious Diseases and AIDS Unit, Hospital Clinic, Barcelona; ²Infectious Diseases Unit, Hospital General Universitario de Valencia, Valencia; ³Department of Internal Medicine, Hospital Universitario de Guadalajara, IDISCAM, Guadalajara; ⁴Department of Pharmacy, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid; ⁵Gilead Sciences SL, Madrid; ⁶Health Value SL, Madrid. Spain

This supplement corrects the following:

José L. Blanco-Arévalo, Miguel García-Deltoro, Miguel Torralba, Manuel Vélez-Díaz-Pallarés, Antonio Castro, Darío Rubio-Rodríguez, and Carlos Rubio-Terrés. HIV-1 resistance and virological failure to treatment with the integrase inhibitors bicitegravir, cabotegravir, and dolutegravir: a systematic literature review. *AIDS Rev.* 2024;26:67-79. doi: 10.24875/AIDSRev.24000011.

Errata correction

Errata 1

In the study by Salazar et al. (2023)³¹, 4 cases (0.34%) of transmitted drug resistance mutations (TDRM) were described in subjects in the first line of treatment with both dolutegravir (DTG) and bicitegravir.

Due to an error in the article, only cases of TDRM observed in subjects receiving DTG were described.

Errata 2

In the last paragraph on page 72 of the article (CAB, VF) reference 25 is incorrect for that particular paragraph. The correct reference would be the following: Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, et al. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. *N Engl J Med.* 2020; 382: 1124-35.

Errata 3

The systematic review included both emerging resistance mutations (produced by the current treatment) and TDRM (not caused by the treatment under study).

*Correspondence to:

Darío Rubio-Rodríguez

Email: crubioterres@healthvalue.org

Received in original form: 16-01-2025

Accepted in final form: 22-01-2025

DOI: 10.24875/AIDSRev.M25000080




Figure 2. VF and HIV-1 RM are associated with drug treatment. Patients without prior ART. For each study, the following data are indicated: name of the first author, year of publication, number of patients in the study, duration of ART, and percentage of VF or MR. ART: antiretroviral treatment; BIC: bicitegravir ART studies; CAB: cabotegravir ART studies; DTG: studies of ART with dolutegravir; N: sample size; NA: data not available or not found in the publication; RM: resistance mutations; VF: virological failure.

By mistake, this was not explicitly mentioned in the article. A total of nine studies with results on TDRM in naïve patients were included in the article (Acosta, 2021³⁰; Álvarez, 2019²⁹; Casadella, 2015⁶⁹; Charpentier, 2021³⁷; Guo, 2021⁷²; Salazar, 2023³¹; Scheibe, 2022³⁸; Tzou, 2020⁶⁸; and Visseaux, 2020⁷¹).

Errata 4

A clarification has been included in figure 2, specifying which drugs the Resistance Mutations bars with an incidence of 0% refers to (Fig. 2 with the clarification indicated).